Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
- U.S. clinic revenue: $18.7M (Greenbrook) - Treatment session revenue: $9.6M - NeuroStar System revenue: $2.8M
The company completed an $18.9M secondary offering in February 2025. Notable developments include CFO Steve Furlong's planned retirement in March 2026, major insurance coverage expansions for adolescent TMS treatment, and achieving over 202,000 global patients treated. Despite a Q1 net loss of $(12.7M), Neuronetics projects becoming cash flow positive in Q3 2025.
For 2025, Neuronetics updated guidance to $149.0M-$155.0M in total revenue, with Q2 2025 expected revenue between $36.0M-$38.0M. The company anticipates year-end cash above $20.0M.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has granted Restricted Stock Units (RSUs) representing 4,500 shares of common stock to three new non-executive employees. The RSUs were approved by the company's Compensation Committee as inducement awards under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. These awards fall under the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced its upcoming first quarter 2025 financial results release. The company will disclose its Q1 2025 financial and operating results before the market opens on Tuesday, May 6, 2025.
A conference call to discuss the results is scheduled for 8:30 a.m. Eastern Time on the same day. Interested parties can access the live broadcast in listen-only mode via webcast, with telephone participants encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM) announced that Evernorth Health Services, a Cigna subsidiary, has expanded coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older with major depressive disorder (MDD). This expansion, effective immediately, impacts 15 million covered lives.
The coverage update follows NeuroStar's FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. Several major insurers, including Humana, Aetna, and Medi-Cal, have updated their policies in response to this clearance.
The expansion addresses a significant need, as approximately 4.3 million U.S. adolescents aged 15-21 are affected by major depression. NeuroStar TMS offers a non-drug treatment option that can be used as a first-line add-on therapy with proven clinical outcomes.
Neuronetics (NASDAQ: STIM) has issued updated financial results for Q4 and full year 2024, revising figures initially reported on March 4, 2025. The revisions, related to the Greenbrook TMS acquisition, include:
For Q4 2024: Operating expenses increased to $26.4M from $25.8M, net loss widened to $(12.7M) from $(12.2M), loss per share increased to $(0.34) from $(0.33), and adjusted EBITDA decreased to $(0.4M) from $0.1M.
For Full Year 2024: Operating expenses rose to $88.7M from $88.2M, net loss expanded to $(43.7M) from $(43.2M), loss per share increased to $(1.38) from $(1.37), and adjusted EBITDA declined to $(21.8M) from $(21.3M).
Neuronetics (NASDAQ: STIM) reported its Q4 and full-year 2024 financial results, highlighting significant strategic developments. The company completed the acquisition of Greenbrook TMS on December 9, 2024, and secured $10 million in additional funding from Perceptive Advisors.
Q4 2024 revenue reached $22.5 million, up 11% year-over-year, with U.S. NeuroStar system revenue at $3.8 million and treatment session revenue at $12.9 million. Full-year 2024 revenue was $74.9 million, a 5% increase from 2023.
The company reported a Q4 net loss of $(12.2) million and a full-year net loss of $(43.2) million. In February 2025, Neuronetics completed a secondary offering raising $18.9 million. The company has executed actions to realize over $21 million of the targeted $22 million in annual cost synergies related to the Greenbrook acquisition.
Looking ahead, Neuronetics projects Q1 2025 revenue between $28-30 million and full-year 2025 revenue of $145-155 million. The company expects to achieve cash flow positivity by Q3 2025.